Quest Diagnostics Incorporated (NYSE: DGX) posted Q3 FY23 adjusted EPS of $2.22, down 5.9% Y/Y, beating the consensus of $2.19.

Sales came in at $2.295 billion, a decline of 7.7% Y/Y, higher than the Wall Street estimate of $2.27 billion.

COVID-19 testing revenues slumped 92% to $26 million, while Base business revenues improved ...

Full story available on Benzinga.com